Mabwell Bioscience

Mabwell Bioscience (688062.SH) is an innovative biopharmaceutical company with a full industry chain layout. Always adhering to the vision of "Turning innovation into reality" and the mission of "Exploring life, benefiting health", it provides patients with better-efficacy and more accessible innovative biological drugs through source innovation, meeting unmet clinical needs worldwide. Since its establishment in 2017, Mabwell has built an innovation system covering the entire drug R&D cycle, starting from antibody drug target discovery and molecular discovery, extending to druggability research, preclinical research, clinical research, and production transformation, achieving an integrated industry chain layout of R&D, production, and marketing. Meanwhile, it has attracted a high-level, diverse, and experienced technical team. Committed to therapeutic areas such as autoimmune diseases, oncology, metabolism, ophthalmology, and infections, relying on international-level five specialty technology platforms and R&D innovation capabilities, it has established a rich and competitive pipeline. Currently, 15 investigational products are at different R&D stages, of which 3 have been submitted for marketing authorization, 3 are in pivotal registration clinical trials, and 6 are in phase I/II clinical trials. The company independently undertakes 1 National Major Science and Technology Project for Significant New Drug Creation, 2 National Key R&D Programs, and multiple provincial/municipal science and technology innovation projects. Mabwell, with innovation as the foundation and focusing on industrial transformation, has its antibody and recombinant protein drug industrialization base in Taizhou, Jiangsu, which meets the GMP standards of China NMPA, US FDA, and EU EMA and has been put into use, and has passed the EU QP audit. A large-scale commercial production base in Shanghai is under construction. In April 2020, it completed a Series A financing of RMB 1.97 billion, and in December 2021, the CSRC approved its IPO registration on the STAR Market.

The company has always upheld the philosophy of innovation, openness, and inclusiveness, bringing together a group of high-level, diverse technical experts from home and abroad. It has established strategic cooperative relationships with institutions such as the Shanghai Institute of Materia Medica of the Chinese Academy of Sciences, Tongji University, Shanghai Jiao Tong University, Fudan University, and other higher education institutions and research institutes. With innovation as the cornerstone, projects as the engine, and employee growth and team building as the foundation, the company has established a multi-level blended talent development and training system. It has tailored three-channel matrix career development paths for talents in professional, management, and project tracks, adhering to a "full participation" project practice mechanism, fostering a strong learning atmosphere of demonstration sharing, communication, and reflection.